| Citation: | Branch of Organ Transplantation of Chinese Medical Association. Technical specifcation for clinical diagnosis and treatment for invasive fungal disease in organ transplant recipients (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 227-236. doi: 10.3969/j.issn.1674-7445.2019.03.002
|
| [1] |
中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)[J].中华内科杂志, 2013, 52(8):704-709. DOI: 10.3760/cma.j.issn.0578-1426.2013.08.030.
Chinese Invasive Fungal Infection Working Group. Diagnosis standard and treatment principle of invasive fungal diseases in patients with hematological malignancy/malignant tumors (fourth revised edition)[J]. Chin J Intern Med, 2013, 52(8):704-709. DOI: 10.3760/cma.j.issn.0578-1426.2013.08.030.
|
| [2] |
GROSSI PA, GASPERINA DD, BARCHIESI F, et al. Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients[J]. Transplant Proc, 2011, 43(6):2463-2471. DOI: 10.1016/j.transproceed.2011.06.020.
|
| [3] |
中华医学会器官移植学分会.实体器官移植患者侵袭性真菌感染的诊断和治疗指南[J].中华器官移植杂志, 2009, 30(7):440-441.DOI: 10.3760/cma.j.issn.0254-1785.2009.07.016.
Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment guideline of invasive fungal infections in solid organ transplant recipients[J]. Chin J Organ Transplant, 2009, 30(7):440-441. DOI: 10.3760/cma.j.issn.0254-1785.2009.07.016.
|
| [4] |
中华医学会器官移植学分会.实体器官移植患者侵袭性真菌感染的诊断和治疗指南(续)[J].中华器官移植杂志, 2009, 30(8):503-506.DOI: 10.3760/cma.j.issn.0254-1785.2009.08.017.
Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment guideline of invasive fungal infections in solid organ transplant recipients (continue) [J]. Chin J Organ Transplant, 2009, 30(8):503-506. DOI: 10.3760/cma.j.issn.0254-1785.2009.08.017.
|
| [5] |
CASTANHEIRA M, MESSER SA, DIETRICH RR, et al. Antifungal susceptibility patterns of a global collection of fungal isolates and polysorbate-80 effect on the susceptibility of the antifungal classes[C]. Philadelphia: Week Meeting of the Infectious Diseases Society of America, 2014: 1454.
|
| [6] |
PAPPAS PG, KAUFFMAN CA, ANDES DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 62(4): e1-e50. DOI: 10.1093/cid/civ933.
|
| [7] |
PERFECT JR, DISMUKES WE, DROMER F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2010, 50(3):291-322. DOI: 10.1086/649858.
|
| [8] |
PATTERSON TF, THOMPSON GR 3RD, DENNING DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4):e1-e60. DOI: 10.1093/cid/ciw326.
|
| [9] |
GAVALDÀ J, MEIJE Y, FORTÚN J, et al. Invasive fungal infections in solid organ transplant recipients[J]. Clin Microbiol Infect, 2014, 20(Suppl 7):27-48. DOI: 10.1111/1469-0691.12660.
|
| [10] |
DE PAUW B, WALSH TJ, DONNELLY JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group[J]. Clin Infect Dis, 2008, 46(12):1813-1821. DOI: 10.1086/588660.
|
| [11] |
PAPPAS PG, ALEXANDER BD, ANDES DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET) [J]. Clin Infect Dis, 2010, 50(8):1101-1111. DOI: 10.1086/651262.
|
| [12] |
NEOFYTOS D, FISHMAN JA, HORN D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients[J]. Transpl Infect Dis, 2010, 12(3):220-229. DOI: 10.1111/j.1399-3062.2010.00492.x.
|
| [13] |
蒋进发, 魏思东, 张宇, 等.肝脏移植术后侵袭性真菌感染的临床特点分析[J].中华医院感染学杂志, 2014, 24(8):1998-2000.DOI: 10.11816/cn.ni.2014-135058.
JIANG JF, WEI SD, ZHANG Y, et al. The clinical characteristics of invasive fungal infections after liver transplantation[J]. Chin J Nosocomiol, 2014, 24(8):1998-2000. DOI: 10.11816/cn.ni.2014-135058.
|
| [14] |
ZICKER M, COLOMBO AL, FERRAZ-NETO BH, et al.Epidemiology of fungal infections in liver transplant recipients: a six-year study of a large Brazilian liver transplantation centre[J]. Mem Inst Oswaldo Cruz, 2011, 106(3):339-345. doi: 10.1590/S0074-02762011000300014
|
| [15] |
LORTHOLARY O, GANGNEUX JP, SITBON K, et al.Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007) [J]. Clin Microbiol Infect, 2011, 17(12):1882-1889. DOI: 10.1111/j.1469-0691.2011.03548.x.
|
| [16] |
MUÑOZ P, CERÓN I, VALERIO M, et al. Invasive aspergillosis among heart transplant recipients: a 24-year perspective[J]. J Heart Lung Transplant, 2014, 33(3):278-288. DOI: 10.1016/j.healun.2013.11.003.
|
| [17] |
BODRO M, SABÉ N, GOMILA A, et al. Risk factors, clinical characteristics, and outcomes of invasive fungal infections in solid organ transplant recipients[J]. Transplant Proc, 2012, 44(9):2682-2685. DOI: 10.1016/j.transproceed.2012.09.059.
|
| [18] |
FORTÚN J, MARTÍN-DÁVILA P, MORENO S, et al. Risk factors for invasive aspergillosis in liver transplant recipients[J]. Liver Transpl, 2002, 8(11):1065-1070. doi: 10.1053/jlts.2002.36239
|
| [19] |
FISHMAN JA, ISSA NC. Infection in organ transplantation: risk factors and evolving patterns of infection[J]. Infect Dis Clin North Am, 2010, 24(2):273-283. DOI: 10.1016/j.idc.2010.01.005.
|
| [20] |
FORTÚN J, MEIJE Y, FRESCO G, et al. Aspergillosis. clinical forms and treatment[J]. Enferm Infecc Microbiol Clin, 2012, 30(4):201-208. DOI: 10.1016/j.eimc.2011.12.005.
|
| [21] |
MONFORTE V, ROMAN A, GAVALDA J, et al. Nebulized amphotericin B prophylaxis for aspergillus infection in lung transplantation: study of risk factors[J]. J Heart Lung Transplant, 2001, 20(12):1274-1281. doi: 10.1016/S1053-2498(01)00364-3
|
| [22] |
MUÑOZ P, RODRÍGUEZ C, BOUZA E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis[J]. Am J Transplant, 2004, 4(4):636-643. doi: 10.1111/ajt.2004.4.issue-4
|
| [23] |
RUIZ-CAMPS I, AGUADO JM, ALMIRANTE B, et al. Guidelines for the prevention of invasive mould diseases caused by filamentous fungi by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) [J].Clin Microbiol Infect, 2011, 17 (Suppl 2):1-24. DOI: 10.1111/j.1469-0691.2011.03477.x.
|
| [24] |
GAVALDÀ J, VIDAL E, LUMBRERAS C. Infection prevention in solid organ transplantation[J]. Enferm Infecc Microbiol Clin, 2012, 30 (Suppl 2):27-33. DOI: 10.1016/S0213-005X(12)70079-4.
|
| [25] |
GAVALDÀ J, MEIJE Y, LEN Ó, et al. Invasive fungal infection in solid organ transplant[J]. Enferm Infecc Microbiol Clin, 2012, 30(10):645-653. DOI: 10.1016/j.eimc.2012.09.004.
|
| [26] |
SALIBA F, DELVART V, ICHAÏ P, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era[J]. Clin Transplant, 2013, 27(4): E454-E461. DOI: 10.1111/ctr.12129.
|
| [27] |
AGUADO JM, RUIZ-CAMPS I, MUÑOZ P, et al. Guidelines for the treatment of invasive candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 update[J]. Enferm Infecc Microbiol Clin, 2011, 29(5):345-361. DOI: 10.1016/j.eimc.2011.01.008.
|
| [28] |
AGUADO JM, VARO E, USETTI P, et al. Safety of anidulafungin in solid organ transplant recipients[J]. Liver Transpl, 2012, 18(6):680-685. DOI: 10.1002/lt.23410.
|
| [29] |
SUN HY, CACCIARELLI TV, SINGH N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients[J]. Transplantation, 2013, 96(6):573-578. DOI: 10.1097/TP.0b013e31829d674f.
|
| [30] |
SALIBA F, FISCHER L, PASCHER A, et al. Micafungin as antifungal prophylaxis in high-risk liver transplantation: randomised multicentre trial [C]. Vienna: 16th Congress of the European Society for Organ Transplantation, 2013: 217.
|
| [31] |
SALIBA F, FISCHER L, PASCHER A, et al. Efficacy and safety of micafungin as antifungal prophylaxis in high-risk liver transplantation [C]. Denver: 53rd International Congress on Antimicrobial Agents and Chemotherapy (ICAAC), 2013: 810.
|
| [32] |
SAN-JUAN R, AGUADO JM, LUMBRERAS C, et al. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients[J]. Transplantation, 2011, 92(3):346-350. DOI: 10.1097/TP.0b013e3182247bb4.
|
| [33] |
MONFORTE V, LÓPEZ-SÁNCHEZ A, ZURBANO F, et al. Prophylaxis with nebulized liposomal amphotericin B for aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant[J]. J Heart Lung Transplant, 2013, 32(3):313-319. DOI: 10.1016/j.healun.2012.11.013.
|
| [34] |
LUONG ML, HOSSEINI-MOGHADDAM SM, SINGER LG, et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients[J]. Am J Transplant, 2012, 12(7):1929-1935. DOI: 10.1111/j.1600-6143.2012.04042.x.
|
| [35] |
SINGER JP, BOKER A, METCHNIKOFF C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients[J]. J Heart Lung Transplant, 2012, 31(7):694-699. DOI: 10.1016/j.healun.2012.02.033.
|
| [36] |
ZWALD FO, SPRATT M, LEMOS BD, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation[J]. Dermatol Surg, 2012, 38(8):1369-1374. DOI: 10.1111/j.1524-4725.2012.02418.x.
|
| [37] |
EPAULARD O, VILLIER C, RAVAUD P, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study[J]. Clin Infect Dis, 2013, 57(12): e182-e188. DOI: 10.1093/cid/cit600.
|
| [38] |
CORNELY OA, BASSETTI M, CALANDRA T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients[J]. Clin Microbiol Infect, 2012, 18 (Suppl 7):19-37. DOI: 10.1111/1469-0691.12039.
|
| [39] |
NETT JE, ANDES DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications[J]. Infect Dis Clin North Am, 2016, 30(1):51-83. DOI: 10.1016/j.idc.2015.10.012.
|
| [40] |
SHOHAM S, MARR KA. Invasive fungal infections in solid organ transplant recipients[J]. Future Microbiol, 2012, 7(5):639-655. DOI: 10.2217/fmb.12.28.
|
| [41] |
CHAU MM, KONG DC, VAN HAL SJ, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014[J]. Intern Med J, 2014, 44(12b):1364-1388. DOI: 10.1111/imj.12600.
|
Figures(4) / Tables(4)
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad:
